Authorization for Aerosols in Diagnostic Nuclear Medicine

This information notice is applicable to all medical radioactive material licensees and broad scope medical licensees who may use Aerosol Tc99m in Uptake, Dilution, or Excretion Studies and/or Imaging and Localization Studies.

Effective immediately, all nuclear pharmacy licensees and medical licensees whose radioactive materials license authorizes Uptake, Dilution, or Excretion Studies under 64E-5.626(1), Florida Administrative Code and/or Imaging and Localization Studies under 64E-5.627(1) F.A.C. will be authorized for Aerosols. Use of Aerosols requires compliance with section 64E-5.629, F.A.C.

All nuclear pharmacy licensees should share this information notice with their clients and advise them that they may obtain a copy directly from the Bureau of Radiation Control website located at www.doh.state.fl.us/environment/radiation/.

Florida determined that this information notice was needed due to a future shortage of Xenon-133 gas. On April 19, 2012, Lantheus Medical Imaging revised their expected supply shortage of Xenon-133 to be for the period of May 16 to May 29, 2012. During this time period, they do not expect to receive replacement supply as their alternative supplier is also unable to provide product during this time period. They anticipate that Xenon-133 will be available by May 30, 2012.

No specific actions or written response is required. If you have any questions or need additional information, please contact us.